Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

about

Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases.A Phase I Trial of the PI3K Inhibitor Buparlisib Combined With Capecitabine in Patients With Metastatic Breast Cancer.

P2860

Q39413866-33FB4CEF-26E5-4367-A319-63E680F62409 Q49886531-D7236A56-5139-45A0-A237-CCE1FC66D17F

P2860

Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

Item

http://www.wikidata.org/entity/Q36575502

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@ast

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@en

type

Item

label

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@ast

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@en

prefLabel

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@ast

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@en

P1476

Clinical Implications of Mutat ...... cer: Prognostic or Predictive?

@en

P2093

Ingrid A Mayer

http://www.w3.org/2001/XMLSchema#string

P2860

Gain of interaction with IRS1 by p110α-helical domain mutants is crucial for their oncogenic functions

The structure of a human p110alpha/p85alpha complex elucidates the effects of oncogenic PI3Kalpha mutations

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms.

PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting.

P2888

s12609-015-0197-9

P304

210-214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12609-015-0197-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26881050

http://www.w3.org/2001/XMLSchema#string

P932

4751984

http://www.w3.org/2001/XMLSchema#string

Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

about

P2860

P2860

Clinical Implications of Mutations in the PI3K Pathway in HER2+ Breast Cancer: Prognostic or Predictive?

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P932